MediPharm Labs Corp. (OTCQX: MEDIF) (TSX: LABS) a international leader in specialized, study-driven pharmaceutical-high-quality cannabis extraction, distillation and derivative merchandise, currently announced it will provide cannabis concentrate merchandise in Denmark to two new healthcare cannabis buyers below two separate white-label agreements. These buyers will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ initially provide agreements for the export of completed merchandise to Denmark.
Denmark granted sufferers legal access to cannabis-primarily based medicinal merchandise two years ago as element of a 4-year pilot plan. The plan offers sufferers with secure solution access and national wellness authorities with patient information that they can use to fully grasp usage and efficacy. According to information and facts complied by New Frontier Information and the Danish Ministry of Overall health, more than two,one hundred sufferers (mainly ladies in between the ages of 42-64) received cannabis-primarily based medicinal merchandise from 429 prescribing medical doctors below this plan in 2019.
“The express goal of establishing a multi-jurisdictional, GMP-certified production capability is to lead the international cannabis marketplace for medicinal, wellness and adult use applications and these agreements represent a further step forward in realizing our ambitions,” mentioned Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish healthcare marketplace with new and revolutionary healthcare cannabis focused merchandise positions us for extra development in Europe and adds to MediPharm Labs all-vital physique of expertise that we are leveraging to improve the design and style of our formulations for sufferers and buyers everywhere.”
Below the agreements, a single which has an initial two-year term and the second a a single-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil merchandise that will be white-labeled for distribution.
MediPharm Labs anticipates delivery to its buyers to start in October 2020, pending regulatory approval by applicable wellness authorities.
GMP Certification Ignites Development for MediPharm Labs Australia
“Since the starting of 2020, MediPharm Labs Australia has secured many quite appealing domestic and international provide agreements with higher high-quality partners, now like new buyers in Denmark,” mentioned Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new company wins are a clear and vital validation of our selection to make a GMP certified cannabis extraction facility provide chain for globe markets and a testament to MediPharm Labs increasing profile and reputation. We appear forward to ramping up production below all of these agreements.”
MediPharm Labs Australia received its Fantastic Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in May possibly 2020, which enables it to sell cannabis APIs and completed merchandise to nations across the EU, like Denmark. The Corporation entered into its initially European white-label cannabis provide agreement that exact same month with Therismos Restricted.
About Denmark’s Healthcare Cannabis Industry
Denmark launched its 4-year healthcare cannabis pilot plan on January 1st, 20181. Post-harvest Fantastic Manufacturing Processes (GMP) is necessary for distribution of healthcare cannabis merchandise in Denmarktwo.
Via the plan, physicians can prescribe healthcare cannabis for all purposes and are guided by suggestions in 4 places: discomfort brought on by various sclerosis, discomfort brought on by spinal cord harm, side effects from chemotherapy therapy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The recommendations published by the Danish Medicines Agency are primarily based on an in depth evaluation of literature as properly as assessments of: cannabis schemes in the Netherlands, Canada and Israel prior cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical high-quality cannabis oil and concentrates and sophisticated derivative merchandise using a Fantastic Manufacturing Practices certified facility with ISO typical constructed clean rooms. MediPharm Labs has invested in an professional, study-driven group, state-of-the-art technologies, downstream purification methodologies and goal-constructed facilities with 5 main extraction lines for delivery of pure, trusted and precision -dosed cannabis merchandise for its buyers. Via its wholesale and white label platforms, they formulate, customer-test, procedure, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based merchandise to domestic and international markets. As a international leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.
Sponsored Content material Release. Click for Complete Disclosure